Brokers Offer Predictions for ACAD Q1 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research note issued on Thursday, February 27th. HC Wainwright analyst A. Fein expects that the biopharmaceutical company will earn $0.10 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $27.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals' Q2 2025 earnings at $0.16 EPS, Q3 2025 earnings at $0.20 EPS, Q4 2025 earnings at $0.24 EPS and FY2029 earnings at $2.32 EPS.

A number of other equities analysts have also weighed in on the company. Deutsche Bank Aktiengesellschaft started coverage on ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They issued a "hold" rating and a $22.00 price target for the company. Guggenheim cut shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $23.00 to $20.00 in a report on Friday, January 3rd. StockNews.com lowered shares of ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday. Cantor Fitzgerald restated an "overweight" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Nine investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.00.

Remove Ads

ACADIA Pharmaceuticals Price Performance

Shares of ACAD traded up $0.10 during trading hours on Friday, hitting $18.26. 1,585,711 shares of the company were exchanged, compared to its average volume of 2,731,150. The firm has a fifty day simple moving average of $18.44 and a 200-day simple moving average of $16.88. The company has a market capitalization of $3.04 billion, a PE ratio of 23.41 and a beta of 0.37. ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $24.27.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several large investors have recently made changes to their positions in ACAD. Creative Planning lifted its stake in ACADIA Pharmaceuticals by 71.4% in the third quarter. Creative Planning now owns 25,061 shares of the biopharmaceutical company's stock valued at $385,000 after acquiring an additional 10,441 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of ACADIA Pharmaceuticals by 11.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 121,625 shares of the biopharmaceutical company's stock valued at $1,871,000 after purchasing an additional 12,787 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of ACADIA Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 1,066 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in ACADIA Pharmaceuticals by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 31,903 shares of the biopharmaceutical company's stock worth $491,000 after purchasing an additional 12,493 shares in the last quarter. Finally, US Bancorp DE increased its position in ACADIA Pharmaceuticals by 2,084.0% during the third quarter. US Bancorp DE now owns 32,934 shares of the biopharmaceutical company's stock worth $507,000 after buying an additional 31,426 shares during the last quarter. Institutional investors own 96.71% of the company's stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.